Lesson plan

3C-FP

3C-FP, also known as 4-(3-fluoropropoxy)-3,5-dimethoxyamphetamine or as α-methylfluoroproscaline (3C-fluoroproscaline), is a psychedelic drug of the phenethylamine, amphetamine, and 3C families related to TMA (3,4,5-TMA). It is the amphetamine (α-methyl) derivative of fluoroproscaline (FP). According to Daniel Trachsel, 3C-FP's dose is 25 mg or more orally and its duration is approximately 8 hours. The specific effects of 3C-FP were not described. The receptor interactions of 3C-FP have been studied. It shows affinity for the serotonin 5-HT 2A and 5-HT 2C receptors (K i = 2,600–4,581 nM and 4,400 nM) and is a potent partial agonist of the serotonin 5-HT 2A receptor ( = 57 nM; = 62%) but not of the serotonin 5-HT 2B receptor ( = >10,000 nM). The chemical synthesis of 3C-FP has been described. 3C-FP was first described in the scientific literature by Trachsel in 2002. Subsequently, its pharmacology as well as its properties in humans were reported by Trachsel and colleagues in 2012, 2013, and 2021.

Back to article

Article summary

3C-FP, also known as 4-(3-fluoropropoxy)-3,5-dimethoxyamphetamine or as α-methylfluoroproscaline (3C-fluoroproscaline), is a psychedelic drug of the phenethylamine, amphetamine, and 3C families related to TMA (3,4,5-TMA). It is the amphetamine (α-methyl) derivative of fluoroproscaline (FP). According to Daniel Trachsel, 3C-FP's dose is 25 mg or more orally and its duration is approximately 8 hours. The specific effects of 3C-FP were not described. The receptor interactions of 3C-FP have been studied. It shows affinity for the serotonin 5-HT 2A and 5-HT 2C receptors (K i = 2,600–4,581 nM and 4,400 nM) and is a potent partial agonist of the serotonin 5-HT 2A receptor ( = 57 nM; = 62%) but not of the serotonin 5-HT 2B receptor ( = >10,000 nM). The chemical synthesis of 3C-FP has been described. 3C-FP was first described in the scientific literature by Trachsel in 2002. Subsequently, its pharmacology as well as its properties in humans were reported by Trachsel and colleagues in 2012, 2013, and 2021.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.